Elisabetta Alafaci

783 total citations
7 papers, 580 citations indexed

About

Elisabetta Alafaci is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Elisabetta Alafaci has authored 7 papers receiving a total of 580 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 2 papers in Pathology and Forensic Medicine. Recurrent topics in Elisabetta Alafaci's work include Lung Cancer Treatments and Mutations (2 papers), Lanthanide and Transition Metal Complexes (1 paper) and Genetic Syndromes and Imprinting (1 paper). Elisabetta Alafaci is often cited by papers focused on Lung Cancer Treatments and Mutations (2 papers), Lanthanide and Transition Metal Complexes (1 paper) and Genetic Syndromes and Imprinting (1 paper). Elisabetta Alafaci collaborates with scholars based in Italy, France and United States. Elisabetta Alafaci's co-authors include S. Brienza, C Jasmin, M. Itzhaki, F Kunstlinger, M Reynès, H. Bismuth, R. Adam, Françis Lévi, J. L. Misset and G. Gruia and has published in prestigious journals such as Journal of neurosurgery, Annals of Oncology and Oral Oncology.

In The Last Decade

Elisabetta Alafaci

6 papers receiving 554 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elisabetta Alafaci Italy 4 473 299 185 152 54 7 580
Aimery de Gramont France 9 428 0.9× 143 0.5× 95 0.5× 120 0.8× 67 1.2× 12 548
Javier Sastre Valera Spain 6 288 0.6× 100 0.3× 82 0.4× 126 0.8× 49 0.9× 15 348
N. E. Kemeny United States 10 406 0.9× 116 0.4× 221 1.2× 131 0.9× 51 0.9× 24 521
A. Schilf France 4 365 0.8× 64 0.2× 96 0.5× 172 1.1× 91 1.7× 7 496
Jean‐Nicolas Munck France 12 214 0.5× 84 0.3× 76 0.4× 70 0.5× 137 2.5× 21 413
A. Fandi France 6 292 0.6× 57 0.2× 108 0.6× 207 1.4× 39 0.7× 7 473
Madhavan V. Pillai United States 7 419 0.9× 49 0.2× 108 0.6× 133 0.9× 49 0.9× 15 512
Ensminger Wd United States 5 180 0.4× 244 0.8× 137 0.7× 89 0.6× 35 0.6× 7 362
М. В. Копп Russia 11 188 0.4× 84 0.3× 56 0.3× 98 0.6× 43 0.8× 16 359
T.C. Kok Netherlands 13 125 0.3× 85 0.3× 266 1.4× 217 1.4× 31 0.6× 20 490

Countries citing papers authored by Elisabetta Alafaci

Since Specialization
Citations

This map shows the geographic impact of Elisabetta Alafaci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisabetta Alafaci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisabetta Alafaci more than expected).

Fields of papers citing papers by Elisabetta Alafaci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisabetta Alafaci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisabetta Alafaci. The network helps show where Elisabetta Alafaci may publish in the future.

Co-authorship network of co-authors of Elisabetta Alafaci

This figure shows the co-authorship network connecting the top 25 collaborators of Elisabetta Alafaci. A scholar is included among the top collaborators of Elisabetta Alafaci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisabetta Alafaci. Elisabetta Alafaci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Morabito, Rosa, Giovanni Grasso, Valeria Barresi, et al.. (2016). Intracranial venous sinus thrombosis as unusual presentation of Bing-Neel syndrome: case illustration. Journal of neurosurgery. 127(5). 1084–1085. 1 indexed citations
2.
Adamo, Vincenzo, Giosafat Spitaleri, Elisabetta Alafaci, et al.. (2005). Phase II Study of Gemcitabine and Cisplatin in Patients with Advanced or Metastatic Bladder Cancer: Long-Term Follow-Up of a 3-Week Regimen. Oncology. 69(5). 391–398. 23 indexed citations
3.
Adamo, Vincenzo, Giuseppa Ferraro, Stefano Pergolizzi, et al.. (2004). Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncology. 40(5). 525–531. 37 indexed citations
4.
Massari, Claire, S. Brienza, J Gastiaburu, et al.. (2000). Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemotherapy and Pharmacology. 45(2). 157–164. 70 indexed citations
5.
Giacchetti, Sylvie, M. Itzhaki, G. Gruia, et al.. (1999). Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Annals of Oncology. 10(6). 663–669. 446 indexed citations
6.
Altavilla, Giuseppe, et al.. (1989). VP16, Epirubicin and Procarbazine in the Treatment of Advanced Non-Small-Cell Lung Cancer. Tumori Journal. 75(2). 168–170. 2 indexed citations
7.
Altavilla, Giuseppe, et al.. (1985). [Serum levels of copper and zinc in patients with lung cancer].. PubMed. 76(44). 2117–20. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026